Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine (original) (raw)
Bernards R (1997) E2F: a nodal point in cell cycle regulation. Biochim Biophys Acta 1333:M33–M40 Google Scholar
Carnero A and Hannon GJ (1997) The INK4 family of CDK inhibitors. In: Vogt PK and Reed SI (eds) Cyclin-dependent kinase (CDK) inhibitors, 1st edn. Springer, Berlin Hidleberg New York, pp 43–56
Chang HM, But PPH (1996) Pharmacology and applications of Chinese materia medica, vol. 2. World Scientific, Singapore
Cheng MP, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ (1999) The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclinD-dependent kinases in murine fibroblasts. EMBO J 18:1571–1583 ArticleCASPubMed Google Scholar
Cohen P (1999) The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos Trans R Soc Lond B Biol Sci 354:485–495 ArticleCASPubMed Google Scholar
Coleman KG, Lyssikatos JP, Yang BV (1997) Chemical inhibitors of cyclin-dependent kinases. Ann Rep Med Chem 32:171–179 CAS Google Scholar
Connell-Crowley L, Harper JW, Goodrich DW (1997) CycinD1/CDK4 regulates retinoblastoma protein mediated cell cycle arrest by specific phosphorylation. Mol Biol Cell 8:287–301 CASPubMed Google Scholar
Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L (2001) Anti-mitotic properties of indirubin-3’-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20:3786–3797 ArticleCASPubMed Google Scholar
Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, Noble ME (2001) Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/Indirubin-5-sulphonate. Structure, 9:389–397
Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511 CASPubMed Google Scholar
Draetta G, Pagano M (1996) Cell cycle control and cancer. Ann Rep Med Chem 31:241–248 CAS Google Scholar
Du D, Ceng Q (1981) Effect of indirubin on the incorporation of isotope labeled precursors into nucleic acid and protein of tumour tissues. Zhongcaoya 12:406–409 CAS Google Scholar
Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F (2000) CDK inhibitors, roscovitine and olomoucine, synergize with farnesyl transferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19:3059–3068 ArticleCASPubMed Google Scholar
Emily-Fenouil F, Ghiglione C, Lhomond G, Lepage T, Gache C (1998) GSK3beta/shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo. Development 125:89–98 Google Scholar
Fiebig HH, Marko D, Eisenbrand G (2001) Indirubins, novel potent inhibitors of cyclin-dependent kinases, inhibit the growth of human xenograft tumours. AACR, 92nd annual meeting, New Orleans, LA, USA
Gan WJ, Yang T, Wen S, Liu Y, Tan Z, Deng C, Wu J, Liu M (1985) Studies on the mechanism of indirubin action in the treatment of chronic myelocytic leukemia (CML). II. 5’-Nucleotidase in the peripheral white blood cells of CML. Chin Acad Med Sci Beijing 6:611–613 CAS Google Scholar
Garrett MD, Fattaey A (1999) CDK inhibition and cancer therapy. Curr Opin Genet Dev 9:104–111 ArticleCASPubMed Google Scholar
Gray N, Detivaud L, Doerig C, Meijer L (1999) ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem 6:859–875 CASPubMed Google Scholar
Han R (1994) Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 12:53–63 CASPubMed Google Scholar
Harbour JW, Dean DC (2000) Rb function in cell-cycle regulation and apoptosis. Nature Cell Biol 2:E65–E67 ArticleCASPubMed Google Scholar
He X, Saint-Jeannet JP, Woodgett HE, Varmus HE, Dawid IB (1995) Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 374:617–22 ArticleCASPubMed Google Scholar
Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1:60–67 CASPubMed Google Scholar
Imahori K, Uchida T (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer’s disease. J Biochem (Tokyo) 121:179–88 Google Scholar
Ji XJ, Zhang FR, Lei JL, Xu YT (1981) Studies on the antineoplastic effect and toxicity of synthetic indirubin. Yaoxue Xuebao 16:146–148 CAS Google Scholar
LaBaer MD, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847–862 CASPubMed Google Scholar
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow E-M, Eisenbrand G, Meijer L (2001) Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in alzheimer’s disease. J Biol Chem 276:251–260 ArticleCASPubMed Google Scholar
Lee K, Shih CY, Yang TY, Chien LS, Chao WM, Sun CS, Wang TC, Pien SK, Sung KH (1979) Ultrastructural study on the mechanism of the therapeutic effect of indirubin for human chronic granulocytic leukemia. Zhinghua Yixue Zazhi 59:129–132 CAS Google Scholar
Li Q (1987) The chemical constituents of Qing Dai. Zhiwu Xuebao 29:67–72 CAS Google Scholar
Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222–231 ArticleCASPubMed Google Scholar
Marko D, Schätzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G (2001) Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 84:283–289 ArticleCASPubMed Google Scholar
Morgan DO (1997) Cyclin- dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291 ArticleCASPubMed Google Scholar
Mueller H, Helin K (2000) The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 1470:M1–M12 Google Scholar
Senderowicz AM, Sausville EA (2000) Preclinical and clinical development of CDK modulators. J Natl Cancer Inst 92:376–387 ArticleCASPubMed Google Scholar
Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149–1163 CASPubMed Google Scholar
Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512 CASPubMed Google Scholar
Sielecki TM, Boylan JF, Benfield PA, Trainor GL (2000) Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 43:1–18 ArticleCAS Google Scholar
Soni R, O’Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B (2001) Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 93:436–446 ArticleCASPubMed Google Scholar
Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE, Birmbaum MJ (1999) The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem 274:17934–17940 ArticleCASPubMed Google Scholar
Tamrakar S, Rubin E, Ludlow JW (2000) Role of pRb dephosphorylation in cell cycle regulation. Front Biosci 5:121–137 Google Scholar
Tang W, Eisenbrand G (1992) Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Springer, Berlin Heidelberg New York Google Scholar
Toledo LM, Lydon NB, Elbaum D (1999) Structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 6:775–805 CASPubMed Google Scholar
Toogood PL (2001) Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 21:487–498 ArticleCASPubMed Google Scholar
Van den Heuvel S, Harlow E (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050–2054 PubMed Google Scholar
Walker DH (1998) Small molecule inhibitors of cyclin-dependent kinases: molecular tools and potential therapeutics. Curr Top Microbiol Immunol 227:149–165 CASPubMed Google Scholar
Wan JH, You YC, Mi JX, Ying HG (1981) Effect of indirubin on hematopoietic cell production. Acta Pharmacol Sin 2:241–244 CAS Google Scholar
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330 CASPubMed Google Scholar
Willert K, Nusse R (1998) Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev 8:95–102 ArticleCASPubMed Google Scholar
Wu GY, Fang FD, Liu JZ, Chang A, Ho YH (1980) Studies on the mechanism of action of indirubin in the treatment of chronic granulocytic leukemia. I. Effects on nucleic acid and protein synthesis in human leukemic cells. Chinese Med J 60:451–454 Google Scholar
Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10:1443–1454 CASPubMed Google Scholar
Zhang S (1983) Studies on the chemical constituents of Isatis indigotica root. Chinese Trad Herb Drugs 14:247–248 CAS Google Scholar
Zhang ZN, Liu EK, Zheng TL, Li DG (1985) Treatment of chronic myelocytic leukemia (CML) by traditional Chinese medicine and Western medicine alternatively. J Trad Chinese Med 5:246–248 CAS Google Scholar
Zheng QT, Lu DJ, Yang SL (1979a) Pharmalogical studies of indirubin. I. Antitumor effect. Comm Chinese Herb Med 10:35–39 Google Scholar
Zheng QT, Qi SB, Cheng ZY (1979b) Pharmacological studies of indirubin. II. Absorption, distribution and excretion of 3H-indirubin. Comm Chinese Herb Med 10:19–21 Google Scholar